Literature DB >> 16844419

Optimization and functional effects of stable short hairpin RNA expression in primary human lymphocytes via lentiviral vectors.

Dong Sung An1, F Xiao-Feng Qin, Vincent C Auyeung, Si Hua Mao, Sam K P Kung, David Baltimore, Irvin S Y Chen.   

Abstract

Specific, potent, and sustained short hairpin RNA (shRNA)-mediated gene silencing is crucial for the successful application of RNA interference technology to therapeutic interventions. We examined the effects of shRNA expression in primary human lymphocytes (PBLs) using lentiviral vectors bearing different RNA polymerase III promoters. We found that the U6 promoter is more efficient than the H1 promoter for shRNA expression and for reducing expression of CCR5 in PBLs. However, shRNA expression from the U6 promoter resulted in a gradual decline of the transduced cell populations. With one CCR5 shRNA this decline could be attributed to elevated apoptosis but another CCR5 shRNA that caused cytotoxicity did not show evidence of apoptosis, suggesting sequence-specific mechanisms for cytotoxicity. In contrast to the U6 promoter, PBLs transduced by vectors expressing shRNAs from the H1 promoter could be maintained without major cytotoxic effects. Since a lower level of shRNA expression appears to be advantageous to maintaining the shRNA-transduced population, lentiviral vectors bearing the H1 promoter are more suitable for stable transduction and expression of shRNA in primary human T lymphocytes. Our results suggest that functional shRNA screens should include tests for both potency and adverse metabolic effects upon primary cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16844419      PMCID: PMC2562632          DOI: 10.1016/j.ymthe.2006.05.015

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  44 in total

1.  siDirect: highly effective, target-specific siRNA design software for mammalian RNA interference.

Authors:  Yuki Naito; Tomoyuki Yamada; Kumiko Ui-Tei; Shinichi Morishita; Kaoru Saigo
Journal:  Nucleic Acids Res       Date:  2004-07-01       Impact factor: 16.971

2.  Molecular basis of organ-specific selection of viral variants during chronic infection.

Authors:  R Ahmed; C S Hahn; T Somasundaram; L Villarete; M Matloubian; J H Strauss
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

Review 3.  How cells respond to interferons.

Authors:  G R Stark; I M Kerr; B R Williams; R H Silverman; R D Schreiber
Journal:  Annu Rev Biochem       Date:  1998       Impact factor: 23.643

4.  Primary human immunodeficiency virus type 1 viremia and central nervous system invasion in a novel hu-PBL-immunodeficient mouse strain.

Authors:  Y Koyanagi; Y Tanaka; J Kira; M Ito; K Hioki; N Misawa; Y Kawano; K Yamasaki; R Tanaka; Y Suzuki; Y Ueyama; E Terada; T Tanaka; M Miyasaka; T Kobayashi; Y Kumazawa; N Yamamoto
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

5.  A pancreatic islet-specific microRNA regulates insulin secretion.

Authors:  Matthew N Poy; Lena Eliasson; Jan Krutzfeldt; Satoru Kuwajima; Xiaosong Ma; Patrick E Macdonald; Sébastien Pfeffer; Thomas Tuschl; Nikolaus Rajewsky; Patrik Rorsman; Markus Stoffel
Journal:  Nature       Date:  2004-11-11       Impact factor: 49.962

6.  A cell line-based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor.

Authors:  A Trkola; J Matthews; C Gordon; T Ketas; J P Moore
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

7.  HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure.

Authors:  J A Zack; S J Arrigo; S R Weitsman; A S Go; A Haislip; I S Chen
Journal:  Cell       Date:  1990-04-20       Impact factor: 41.582

Review 8.  Vectors for RNA interference.

Authors:  Renu Wadhwa; Sunil C Kaul; Makoto Miyagishi; Kazunari Taira
Journal:  Curr Opin Mol Ther       Date:  2004-08

9.  In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector.

Authors:  L Naldini; U Blömer; P Gallay; D Ory; R Mulligan; F H Gage; I M Verma; D Trono
Journal:  Science       Date:  1996-04-12       Impact factor: 47.728

10.  Short-term cytotoxic effects and long-term instability of RNAi delivered using lentiviral vectors.

Authors:  Richard J Fish; Egbert K O Kruithof
Journal:  BMC Mol Biol       Date:  2004-08-03       Impact factor: 2.946

View more
  79 in total

Review 1.  The use of cell-delivered gene therapy for the treatment of HIV/AIDS.

Authors:  Geoff P Symonds; Helen A Johnstone; Michelle L Millington; Maureen P Boyd; Bryan P Burke; Louis R Breton
Journal:  Immunol Res       Date:  2010-12       Impact factor: 2.829

2.  Stable Delivery of CCR5-Directed shRNA into Human Primary Peripheral Blood Mononuclear Cells and Hematopoietic Stem/Progenitor Cells via a Lentiviral Vector.

Authors:  Saki Shimizu; Swati Seth Yadav; Dong Sung An
Journal:  Methods Mol Biol       Date:  2016

3.  Combined preconditioning and in vivo chemoselection with 6-thioguanine alone achieves highly efficient reconstitution of normal hematopoiesis with HPRT-deficient bone marrow.

Authors:  Katrin Hacke; Akos Szakmary; Andrew R Cuddihy; Nora Rozengurt; Nathan A Lemp; Jiri Aubrecht; Gregory W Lawson; Nagesh P Rao; Gay M Crooks; Robert H Schiestl; Noriyuki Kasahara
Journal:  Exp Hematol       Date:  2011-10-12       Impact factor: 3.084

4.  Stable reduction of CCR5 by RNAi through hematopoietic stem cell transplant in non-human primates.

Authors:  Dong Sung An; Robert E Donahue; Masakazu Kamata; Betty Poon; Mark Metzger; Si-Hua Mao; Aylin Bonifacino; Allen E Krouse; Jean-Luc Darlix; David Baltimore; F Xiao-Feng Qin; Irvin S Y Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-01       Impact factor: 11.205

5.  Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo.

Authors:  Ryan L Boudreau; Inês Martins; Beverly L Davidson
Journal:  Mol Ther       Date:  2008-11-11       Impact factor: 11.454

Review 6.  Lentiviral vector-mediated RNA silencing in the central nervous system.

Authors:  Thomas H Hutson; Edmund Foster; Lawrence D F Moon; Rafael J Yáñez-Muñoz
Journal:  Hum Gene Ther Methods       Date:  2013-11-01       Impact factor: 2.396

Review 7.  Short non-coding RNA biology and neurodegenerative disorders: novel disease targets and therapeutics.

Authors:  Marc S Weinberg; Matthew J A Wood
Journal:  Hum Mol Genet       Date:  2009-04-15       Impact factor: 6.150

8.  A highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model.

Authors:  Saki Shimizu; Patrick Hong; Balamurugan Arumugam; Lauren Pokomo; Joshua Boyer; Naoya Koizumi; Panyamol Kittipongdaja; Angela Chen; Greg Bristol; Zoran Galic; Jerome A Zack; Otto Yang; Irvin S Y Chen; Benhur Lee; Dong Sung An
Journal:  Blood       Date:  2009-12-17       Impact factor: 22.113

9.  Comprehensive evaluation of the role of EZH2 in the growth, invasion, and aggression of a panel of prostate cancer cell lines.

Authors:  Breanne D W Karanikolas; Marxa L Figueiredo; Lily Wu
Journal:  Prostate       Date:  2010-05-01       Impact factor: 4.104

Review 10.  RNA interference-based therapeutics for human immunodeficiency virus HIV-1 treatment: synthetic siRNA or vector-based shRNA?

Authors:  Sandesh Subramanya; Sang-Soo Kim; N Manjunath; Premlata Shankar
Journal:  Expert Opin Biol Ther       Date:  2010-02       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.